Heron Therapeutics (HRTX) Competitors $1.30 +0.02 (+1.56%) Closing price 04:00 PM EasternExtended Trading$1.28 -0.02 (-1.15%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HRTX vs. SYRE, MNMD, DNA, RLAY, SANA, BGM, BCAX, SEPN, CRMD, and ANABShould you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include Spyre Therapeutics (SYRE), Mind Medicine (MindMed) (MNMD), Ginkgo Bioworks (DNA), Relay Therapeutics (RLAY), Sana Biotechnology (SANA), BGM Group (BGM), Bicara Therapeutics (BCAX), Septerna (SEPN), CorMedix (CRMD), and AnaptysBio (ANAB). These companies are all part of the "pharmaceutical products" industry. Heron Therapeutics vs. Its Competitors Spyre Therapeutics Mind Medicine (MindMed) Ginkgo Bioworks Relay Therapeutics Sana Biotechnology BGM Group Bicara Therapeutics Septerna CorMedix AnaptysBio Spyre Therapeutics (NASDAQ:SYRE) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment. Which has more risk & volatility, SYRE or HRTX? Spyre Therapeutics has a beta of 2.9, suggesting that its stock price is 190% more volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Does the media prefer SYRE or HRTX? In the previous week, Spyre Therapeutics had 2 more articles in the media than Heron Therapeutics. MarketBeat recorded 8 mentions for Spyre Therapeutics and 6 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.30 beat Spyre Therapeutics' score of 0.46 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Heron Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of SYRE or HRTX? 80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 6.2% of Spyre Therapeutics shares are held by company insiders. Comparatively, 5.9% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is SYRE or HRTX more profitable? Spyre Therapeutics has a net margin of 0.00% compared to Heron Therapeutics' net margin of -0.62%. Heron Therapeutics' return on equity of 0.00% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spyre TherapeuticsN/A -71.30% -38.69% Heron Therapeutics -0.62%N/A -0.40% Do analysts rate SYRE or HRTX? Spyre Therapeutics presently has a consensus target price of $54.29, suggesting a potential upside of 186.92%. Heron Therapeutics has a consensus target price of $4.50, suggesting a potential upside of 246.15%. Given Heron Therapeutics' higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Spyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyre Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00Heron Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has preferable earnings & valuation, SYRE or HRTX? Heron Therapeutics has higher revenue and earnings than Spyre Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpyre Therapeutics$890K1,284.01-$208.02M-$3.40-5.56Heron Therapeutics$144.29M1.65-$13.58M-$0.02-65.00 SummarySpyre Therapeutics beats Heron Therapeutics on 10 of the 17 factors compared between the two stocks. Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRTX vs. The Competition Export to ExcelMetricHeron TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$234.64M$2.60B$6.04B$10.28BDividend YieldN/A57.78%5.73%4.81%P/E Ratio-65.004.7363.5822.85Price / Sales1.65755.26612.85138.67Price / CashN/A25.7125.7330.17Price / Book-5.915.3212.666.69Net Income-$13.58M$32.98M$3.31B$276.03M7 Day Performance-2.99%0.94%-0.44%-1.13%1 Month Performance3.17%9.70%8.70%6.49%1 Year Performance-29.35%-0.42%76.70%34.41% Heron Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRTXHeron Therapeutics3.981 of 5 stars$1.30+1.6%$4.50+246.2%-30.4%$234.64M$144.29M-65.00300News CoveragePositive NewsSYRESpyre Therapeutics3.1777 of 5 stars$16.67+4.9%$54.29+225.6%-33.3%$959.77M$890K-4.9073MNMDMind Medicine (MindMed)2.4622 of 5 stars$12.22-2.7%$26.50+116.9%+118.3%$955.66MN/A-7.9940Analyst ForecastDNAGinkgo Bioworks1.1778 of 5 stars$14.87-7.9%$9.00-39.5%+84.4%$955.48M$227.04M-2.54640RLAYRelay Therapeutics2.5781 of 5 stars$5.59+2.0%$16.50+195.2%-4.4%$944.82M$10.01M-2.87330News CoveragePositive NewsSANASana Biotechnology2.8755 of 5 stars$4.16+5.1%$7.50+80.3%+8.3%$941.71MN/A-3.92380BGMBGM Group0.5591 of 5 stars$9.70+1.4%N/A+29.9%$930.42M$25.10M0.00298Gap DownBCAXBicara Therapeutics1.7832 of 5 stars$18.03+5.8%$32.25+78.9%-8.4%$929.75MN/A0.0032News CoverageInsider TradeGap UpSEPNSepterna0.8456 of 5 stars$20.80+0.6%$26.75+28.6%N/A$922.02M$1.08M-2.06N/AHigh Trading VolumeCRMDCorMedix2.8246 of 5 stars$11.56+1.9%$18.00+55.7%+6.0%$885.19M$43.47M15.4130Analyst DowngradeANABAnaptysBio2.4564 of 5 stars$30.25-2.2%$48.75+61.2%-5.6%$866.23M$91.28M-6.75100Analyst ForecastAnalyst RevisionGap Up Related Companies and Tools Related Companies Spyre Therapeutics Competitors Mind Medicine (MindMed) Competitors Ginkgo Bioworks Competitors Relay Therapeutics Competitors Sana Biotechnology Competitors BGM Group Competitors Bicara Therapeutics Competitors Septerna Competitors CorMedix Competitors AnaptysBio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HRTX) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
